A
Alexion Pharmaceuticals
World Leader in Treatments for Patients with Devastating and Rare Diseases
At a glance
- Founded
- 1992
- Headquarters
- Boston, United States
- Listing
- IPO 1996
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Alexion Pharmaceuticals.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- CPCHL Medical Partners
- INInvesco
- OPOak Investment Partners
Series B and later1 investor entered at this stage
- YUYale University
Source: Dealroom Talent Intelligence.
Alumni founders
Former Alexion Pharmaceuticals employees who went on to found companies, sorted by Dealroom signal score.
DTDyne TherapeuticsEst. 2017
Romesh SubramanianUnited States
POPoxelEst. 2009
Pascale FouquerayFrance
ELElevateBioEst. 2018
David HallalUnited States
RARallybioEst. 2018
Jeffrey FryerUnited States
BMBeeline MedicinesEst. 2025
Saqib IslamUnited StatesGlobal footprint
team presence
across markets
Patents
254 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Alexion Pharmaceuticals was the backer or acquirer, 2011–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
8 deals across Alexion Pharmaceuticals's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Alexion Pharmaceuticals deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Alexion Pharmaceuticals's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alexion Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alexion Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.